Consistent with the charter of the Bronowski Institute of Behavioural Neuroscience the staff of the Bronowski Clinic are devoted to disseminating their knowledge and experience to improve the quality of life in people with Parkinson’s disease and other disorders. To achieve this we provide professional support for medical doctors, psychologists, clinicians and other health professionals in their routine practice of treating any disorder that respond to the implementation of phototherapy.
We not only provide professional advice on strategic light use as an adjuvant treatment in Parkinson’s disease but we continue to explore other applications of this non-invasive treatment to help in other conditions such as the Parkinson’s Plus disorders, Multiple Sclerosis, insomnia, depression, Huntington’s chorea and Tourette’s Syndrome. We have also found many instances whereby the comorbid states of many disease that include insomnia and depression can be improved by strategic light therapy where drug intervention has failed.
We have also found that critical factors such as time of light administration during the day/night cycle, duration of treatment and technical aspects of light administration that have not been addressed to optimise chronotherapeutics. Consequently, are we are now refining the application of light therapy so as to compliment traditional approached to treatment of many disorders.
In doing so we are defining a new approach for developing best management practices for applying bright light therapy in the treatment of anxiety, depression and insomnia not only as comorbidities of Parkinson’s disease but also in other conditions as well as being treated as mental conditions in their own right.
In our most recent work, we have unveiled the therapeutic and adverse effects of phototherapy in such detail that we believe light should be regarded as a “drug” in that under dosing, effective dosing and overdosing can result in a response by patients much resembling that occurring with pharmacological intervention. This is particularly important when applying a new treatment to any disorder given that individual sensitivity to drugs can vary from patient to patient and strategic light therapy can elicit the same response.
We are also developing an approach for treating drug overdosing phenomena with strategic drug titration that will aid in reducing polypharmacy in drug addiction, drug over-prescription and also to reduce the need for invasive forms of surgical intervention, such as DBS.
We are currently developing a comprehensive guide describing the key to more effectively treating depression, insomnia and other neurological and psychiatric disorders using the chronotherapeutic approach. This will describe a description of long and short term methodologies for the application of bright light therapy for symptomatic treatment and even slowing the progression of desiderative disease states.
As a research clinic we welcome any person whom remains trouble by common derivatives of many complaints such as insomnia, depression or anxiety, whether they exist they in their own right or they be part of another, more complex disorder.
We are here to serve those who have a compromised quality of life and we will be pleased to provide what service we are able, no matter where you reside.
So please make contact, if you feel we may be of some help in improving your quality of life.
Dr Greg Willis
Clinical Director
The Bronowski Clinic
| Address | Appointments | Telephone | |
|---|---|---|---|
| The Bronowski Clinic 40 Davy St Woodend,3442, VIC, Australia |
Dr. Greg Willis +61 411514980 International 0411514980 Australia |
+61 3 5427 1494 International (03) 5427 1494 Australia |
director@bronowski.org |
A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease.
Willis GL, Armstrong SM
Physiol. Behav. 66 (5):785-95, 1999.
Therapeutic effects of bright light therapy in Parkinson’s disease: A series of case reports.
Willis, G.L. and McLennan, C.A.
Melatonin and Biological Rhythms Symposium, Australian Chronobiology Society, Adelaide, South Australia, August 21-23, p.015, 2001.
Principles emerging from the clinical use of bright light therapy as the fundamental ingredient in treatment strategies for Parkinson’s disease: an update.
Willis, GL and Turner, EJD
Australian Chronobiology Society Conference, Melbourne, Victoria p14, 2006.
The Role of Psychologists in the Assessment and Treatment of Parkinson’s disease: Returning Quality of Life to the Elderly with Neuropsychiatric Disorders”,
Willis, GL
Australian Psychological Society, Psychology and Aging Interest Group, October, 2007
Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study.
Willis GL, Turner EJ.
Chronobiol. Int. 2007; 24 (3):521-37.
The therapeutic effect of monochromatic blue light on the features of Parkinson’s disease using a quasi-blind strategy.
Willis, GL
Australian Chronobiology Society-5th Annual Meeting, Sydney, Australia, p. 20b, 2008.
Parkinson’s disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process.
Willis GL
Rev. Neurosci. 2008; 19 (4-5):245-316. Review.
Can long-term light therapy slow the progressive degeneration of Parkinson’s disease?
Willis, GL, Moore C Armstrong SM
Australian Chronobiology Society-6th Annual Meeting, Melbourne, Australia, p. 23, 2009.
New Vistas on Parkinson’s disease.
Willis GL, Armstrong SM
Eur. J. Neurol. 2010 Apr;17 (4):519-20. doi: 10.1111/j.1468-1331.2009.02852.x. Epub 2009 Nov 18. No abstract available.
The therapeutic effect of strategic long term light therapy in Parkinson’s disease,
GL Willis, GL, Moore C, Armstrong, SM,
Australian Chronobiology Society-8th Annual Meeting, Melbourne, Australia, p. 6, 2011.
A historical justification for and retrospective analysis of the systematic application of light therapy in Parkinson’s disease.
Willis GL, Moore C, Armstrong SM
Rev. Neurosci. 2012 Mar 1; 23 (2):199-226. doi: 10.1515/revneuro-2011-0072.
Breaking away from dopamine deficiency: an essential new direction for Parkinson’s disease.
Willis GL, Moore C, Armstrong SM
Rev. Neurosci. 2012; 23 (4):403-28. doi: 10.1515/revneuro-2012-0037. Review.
The origins of the study of circadian involvement in neuropsychiatric disease.
Willis GL
Invited Plenary Lecture, Australian Chronobiology Society, Adelaide, S.S., August 13-14, 2017.
Circadian system – A novel diagnostic and therapeutic target in Parkinson’s disease?
Videnovic A, Willis GL
Mov. Disord. 2016 Mar; 31 (3):260-9. doi: 10.1002/mds.26509. Epub 2016 Jan 30. Review.
Emerging preclinical interest concerning the role of circadian function in Parkinson’s disease.
Willis GL, Freelance CB
Brain. Res. 2018 Jan 1; 1678: 203-213. doi: 10.1016/j.brainres.2017.09.027. Epub 2017 Sep 25. Review.
The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study.
Martino JK, Freelance CB, Willis GL
Sleep Med. 2018 Apr; 44: 24-31. doi: 10.1016/j.sleep.2018.01.001. Epub 2018 Jan 31.
Light as a Therapeutic in the Treatment and Management of Parkinson’s Disease: A Controlled Exploratory Trial.
Willis GL, Boda J & Freelance CB. Front. Neurol. (2018) 9:741. doi: 10.3389/fneur.2018.00741
Bright light therapy in Parkinson’s disease: a pilot study. Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Mov Disord. (2007) Jul 30;22(10):1495-8.
Timed light therapy for sleep and daytime sleepiness associated with Parkinson disease a randomized clinical trial. Videnovic A, Klerman E, Wang W Marconi A, Kuhta T, Zee P. JAMA Neurology (2017) 74(4) 411-418 DOI: 10.1001/jamaneurol.2016.5192.
Bright light therapy for depression in Parkinson disease: A randomized controlled trial. Rutten S, Vriend C, Smit J, Berendse H, Van Someren E, Hoogendoorn A, Twisk J, Van Der Werf Y, Van Den Heuvel O. Neurology (2019) 92(11) E1145-E1156 DOI: 10.1212/WNL.0000000000007090.
Bright light therapy with a head-mounted device for anxiety, depression, sleepiness and fatigue in patients with Parkinson’s disease. Raymackers JM, Andrade M, Baey E, Vanneste M, Evrard F. Acta Neurol Belg. (2019) Dec;119(4):607-613. doi: 10.1007/s13760-019-01214-3.
© Copyright 2015 The Bronowski Institute. All Rights Reserved. Terms & Conditions.
Any information or data found on this website may not be reused without the permission of the Public Liaison Officer of the Institute.
Information on this website is for use as a source of information only, and does not constitute medical advice.
Website developed by MRGraphics.